Radius Health to Present at the BIO-Europe Spring 2015 Paris Expo March 9-11, 2015

WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its Vice President, Business Development & Strategy, Geoffrey A. Swire, will present at the BIO-Europe Spring 2015 Paris Expo Conference on Tuesday, March 10, 2015 at 5:00 p.m. Central European Time at the Porte de Versailles, Paris, France.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company's lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com.

CONTACT: Investor Relations Barbara Ryan Clermont Partners Partner 203-274-2825 bryan@radiuspharm.comSource:Radius Health